Nebivolol, a third generation selective β1-adrenoceptor (β1-AR) antagonist, has been
reported to reduce intracellular oxidative stress and to induce the release of nitric oxide (NO) …

Objective—dl-Nebivolol, a selective β1-adrenergic receptor antagonist, besides its
hypotensive activity exerts vasodilatory and platelet inhibitory effects in vitro by a mechanism …

The sympathetic system is central in the understanding of numerous physiological and
physiopathological phenomena. During the last decade, the characterization of a new β …

Metabolic syndrome, a “cluster” of metabolic disorders including hypertension, increases the
cardiovascular risk, and insulin resistance plays a key role in its pathogenesis. In this …

Nebivolol is a highly selective β 1-adrenoceptor blocker, which also stimulates endothelial
nitric oxide synthase and scavenges reactive oxygen species (ROS). These characteristics …

Background and purpose: Nebivolol is a highly selective β1‐adrenoceptor antagonist with
β3‐adrenoceptor agonist properties and is a racemate mixture of D‐and L‐enantiomers …

Nebivolol is a highly selective beta1-adrenergic blocker that also enhances nitric oxide
bioavailability via the L-arginine-nitric oxide pathway, leading to vasodilation and decreased …

Asymmetric dimethylarginine (ADMA) has been reported to affect the synthesis of nitric oxide
(NO) in endothelial cells by inhibiting endothelial NO synthase (eNOS) activity and to cause …

Nebivolol has been shown to be beneficial in the treatment of cardiovascular diseases such
hypertension, congestive heart failure, arterial stiffness and endothelial dysfunction. The …

Objectives: The aim of the present study was to analyze whether beta3-adrenoceptors (β3-
ARs) were effectively present and functional in the human internal mammary artery (IMA) …